Novonesis (Novozymes) A/S (NSIS-B) - Total Liabilities
Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) has total liabilities worth Dkr5.60 Billion DKK (≈ $876.71 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Novonesis (Novozymes) A/S - Total Liabilities Trend (2002–2025)
This chart illustrates how Novonesis (Novozymes) A/S's total liabilities have evolved over time, based on quarterly financial data. See NSIS-B working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Novonesis (Novozymes) A/S Competitors by Total Liabilities
The table below lists competitors of Novonesis (Novozymes) A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Texas Pacific Land Corporation
NYSE:TPL
|
USA | $195.51 Million |
|
HEXAGON AB ADR/1
F:HXGC
|
Germany | €5.93 Billion |
|
Telefónica S.A
MX:TEFN
|
Mexico | MX$71.22 Billion |
|
Constellation Brands Inc Class A
NYSE:STZ
|
USA | $13.51 Billion |
|
CGN Power
SHE:003816
|
China | CN¥327.94 Billion |
|
Naver Corporation
KO:035420
|
Korea | ₩12.13 Trillion |
|
Hana Financial
KO:086790
|
Korea | ₩614.08 Trillion |
|
Reddit, Inc.
NYSE:RDDT
|
USA | $310.13 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Novonesis (Novozymes) A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Novonesis (Novozymes) A/S.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novonesis (Novozymes) A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novonesis (Novozymes) A/S (2002–2025)
The table below shows the annual total liabilities of Novonesis (Novozymes) A/S from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr5.49 Billion ≈ $859.56 Million |
+36.68% |
| 2024-12-31 | Dkr4.02 Billion ≈ $628.90 Million |
-71.37% |
| 2023-12-31 | Dkr14.04 Billion ≈ $2.20 Billion |
+2.07% |
| 2022-12-31 | Dkr13.76 Billion ≈ $2.15 Billion |
+9.51% |
| 2021-12-31 | Dkr12.56 Billion ≈ $1.97 Billion |
+35.56% |
| 2020-12-31 | Dkr9.27 Billion ≈ $1.45 Billion |
+3.45% |
| 2019-12-31 | Dkr8.96 Billion ≈ $1.40 Billion |
+8.45% |
| 2018-12-31 | Dkr8.26 Billion ≈ $1.29 Billion |
+16.23% |
| 2017-12-31 | Dkr7.11 Billion ≈ $1.11 Billion |
+2.78% |
| 2016-12-31 | Dkr6.91 Billion ≈ $1.08 Billion |
+11.55% |
| 2015-12-31 | Dkr6.20 Billion ≈ $969.72 Million |
-13.27% |
| 2014-12-31 | Dkr7.15 Billion ≈ $1.12 Billion |
+31.36% |
| 2013-12-31 | Dkr5.44 Billion ≈ $851.13 Million |
-1.89% |
| 2012-12-31 | Dkr5.54 Billion ≈ $867.56 Million |
+10.50% |
| 2011-12-31 | Dkr5.02 Billion ≈ $785.10 Million |
+5.49% |
| 2010-12-31 | Dkr4.76 Billion ≈ $744.27 Million |
-5.60% |
| 2009-12-31 | Dkr5.04 Billion ≈ $788.39 Million |
-7.52% |
| 2008-12-31 | Dkr5.45 Billion ≈ $852.54 Million |
+4.71% |
| 2007-12-31 | Dkr5.20 Billion ≈ $814.20 Million |
+13.82% |
| 2006-12-31 | Dkr4.57 Billion ≈ $715.32 Million |
+30.07% |
| 2005-12-31 | Dkr3.52 Billion ≈ $549.95 Million |
+8.42% |
| 2004-12-31 | Dkr3.24 Billion ≈ $507.23 Million |
-6.25% |
| 2003-12-31 | Dkr3.46 Billion ≈ $541.03 Million |
-15.70% |
| 2002-12-31 | Dkr4.10 Billion ≈ $641.79 Million |
-- |
About Novonesis (Novozymes) A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The c… Read more